Uroplasminogen Receptor (uPAR) IHC Study in Triple Negative Breast Carcinoma
GM Oprea-Ilies, SE Pambuccian, R Gamez, A Young, C Cohen. Emory University, Atlanta, GA; Univeristy of Minnesota, Minneapolis, MN
Background: The uroplasminogen activator system is thought to play a role in several different processes important to tumor progression, including tumor growth, angiogenesis and metastasis. UPAR is expressed in most solid tumors and was described as portending worse prognosis in hormone receptors positive breast cancer (BC). The aim of this study is to asses d the presence of uPAR expression in triple negative breast cancers (TNTBC) in comparison with other phenotypic markers and patients' racial background.
Design: Tissue microarrays from 125 BC diagnosed during a 6 year period were studied. Only tumors that did not show staining for ER, PR and were scored as 0, 1 or 2 with FISH confirmation for non-amplified HER2 were included. Immunohistochemical (IHC) staining was performed for cytokeratin (CK) 5/6, 7, 8, 14, 18, 19, vimentin, CD44, survivin, c-kit and p53. Clinical pathologic data included race, age, and TNM staging. Statistical analysis: Pearson correlation coeficient was used, using a 2 tailed p value of .05 as significant.
Results: Our patients included 107 African-American (AA) and 18 Caucasians (CS) women. The age range was 28-83 in AA and 18-80 in CS group, with an average of 50 year old and 40 year old respecively. Overall 41% women were younger than 50 year of age. UPAR staining was observed in 41/90 (46%) of AA and 3/10 (30%) of CS patients. Overall in the four groups we found a positive correlation between the percentage of UPAR and the percenatge of Ki67 staining.
This positive correlation is also present for the AA younger than 50 group (CC of .306, p val < .013), but not observed in the AA women older than 50 year of age. This positive correlation was present in both, the CS younger than 50 yo group (CC .249, p val < .012) and in the CS older than 50 yo group (CC of .233, p val < .023)
Conclusions: 1. UPAR was positively correlated with proliferative rate which is one of the most important prognostic factors for breast cancer. 2. This suggests that targeted anti-UPAT therapy may be beneficial in a subgroup of patients with TNBC, as this group does not benefit form other any specific therapy.
Tuesday, March 23, 2010 1:00 PM
Poster Session IV # 3, Tuesday Afternoon